4.8 Article

Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function

期刊

GASTROENTEROLOGY
卷 149, 期 1, 页码 190-+

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2015.03.004

关键词

Immune Regulation; NS5A Inhibitor; NS3 Inhibitor; ISG

资金

  1. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, intramural research program

向作者/读者索取更多资源

BACKGROUND & AIMS: Chronic hepatitis C virus infection activates an intrahepatic immune response, leading to increased expression of interferon (IFN)-stimulated genes and activation of natural killer (NK) cells-the most prevalent innate immune cell in the liver. We investigated whether the elimination of hepatitis C virus with direct-acting antiviral normalizes expression of IFN-stimulated genes and NK cell function. METHODS: We used multicolor flow cytometry to analyze NK cells from the liver and blood of 13 HCV-infected patients who did not respond to treatment with pegylated interferon and ribavirin. Samples were collected before and during IFN-free treatment with daclatasvir and asunaprevir and compared with samples from the blood of 13 healthy individuals (controls). Serum levels of chemokine C-X-C motif ligand (CXCL) 10 or CXCL11 were measured by enzyme-linked immunosorbent assay. RESULTS: Before treatment, all patients had increased levels of CXCL10 or CXCL11 and a different NK cell phenotype from controls, characterized by increased expression of HLA-DR, NKp46, NKG2A, CD85j, signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). NK cells from patients also had increased degranulation and decreased production of IFN gamma and tumor necrosis factor alpha compared with NK cells from controls. Nine patients had an end-of-treatment response (undetectable virus) and 4 had virologic breakthrough between weeks 4 and 12 of therapy. A rapid decrease in viremia and level of inflammatory cytokines in all patients was associated with decreased activation of intrahepatic and blood NK cells; it was followed by restoration of a normal NK cell phenotype and function by week 8 in patients with undetectable viremia. This normalized NK cell phenotype was maintained until week 24 (end of treatment). CONCLUSIONS: Direct-acting antiviral-mediated clearance of HCV is associated with loss of intrahepatic immune activation by IFN alpha, which is indicated by decreased levels of CXCL10 and CXCL11 and normalization of NK cell phenotype and function.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection

Raymond T. Chung, Wendy C. King, Marc G. Ghany, Mauricio Lisker-Melman, Amanda S. Hinerman, Mandana Khalili, Mark Sulkowski, Mamta K. Jain, Eun-Young K. Choi, Michael A. Nalesnik, Atul K. Bhan, Gavin Cloherty, David K. Wong, Richard K. Sterling

Summary: This study evaluated the role of HBV RNA and HBcrAg in characterizing HBV-HIV coinfection and found that the use of novel HBV markers can continue to improve the suppression of HBV transcription and translation in suppressive dually active antiviral therapy. However, for HBeAg patients, the benefit of combination antiviral therapy is limited.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Untitled Reply

Marc G. Ghany, Wendy C. King, Mauricio Lisker-Melman, Anna S. F. Lok, Norah Terrault, Harry L. A. Janssen, Mandana Khalili, Raymond T. Chung, William M. Lee, Daryl T. Y. Lau, Gavin A. Cloherty, Richard K. Sterling

HEPATOLOGY (2022)

Review Gastroenterology & Hepatology

Review article: hepatitis B-current and emerging therapies

David Yardeni, Marc G. Ghany

Summary: This review provides a concise overview of current and emerging treatment options for chronic hepatitis B. Currently approved treatments do not offer a complete cure, but recent advancements in viral lifecycle understanding and drug delivery technologies have led to the development of novel therapeutic approaches that are currently being evaluated in clinical trials.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Letter Gastroenterology & Hepatology

Chronic Hepatitis B and Fatty Liver-Weal or Woe? Reply

Mandana Khalili, David E. Kleiner, Wendy C. King, Richard K. Sterling, Marc G. Ghany, Raymond T. Chung, Atul K. Bhan, Philip Rosenthal, Mauricio Lisker-Melman, Rageshree Ramachandran, Anna S. Lok

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

Article Infectious Diseases

A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)-HIV co-infection with high prevalence of tenofovir-based antiretroviral therapy use

Andinet Gizaw, Wendy C. King, Amanda S. Hinerman, Raymond T. Chung, Mauricio Lisker-Melman, Marc G. Ghany, Mandana Khalili, Mamta K. Jain, Jacob Graham, Theresa Swift-Scanlan, David E. Kleiner, Mark Sulkowski, David K. Wong, Richard K. Sterling

Summary: This study suggests that TDF use in HBV-HIV co-infected adults can lead to worsening renal function and bone turnover.

HIV MEDICINE (2023)

Article Gastroenterology & Hepatology

HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy

Mauricio Lisker-Melman, Abdus S. Wahed, Marc G. Ghany, Raymond T. Chung, Wendy C. King, David E. Kleiner, Atul K. Bhan, Mandana Khalili, Mamta K. Jain, Mark Sulkowski, David K. Wong, Gavin Cloherty, Richard K. Sterling

Summary: In patients coinfected with HBV and HIV, HBV RNA and HBcrAg can still be detected despite viral suppression, and their levels are associated with the extent of HBsAg and HBcAg staining in liver cells. This suggests that residual transcription and translation may contribute to liver pathology even when viral replication is suppressed.

HEPATOLOGY (2023)

Review Gastroenterology & Hepatology

Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure

David Yardeni, Kyong-Mi Chang, Marc G. Ghany

Summary: Hepatitis B virus is a major cause of cirrhosis and hepatocellular carcinoma, and despite the availability of an effective vaccine, chronic infection continues to be prevalent. Current therapies are effective at suppressing the virus during treatment, but do not provide long-term viral suppression. There is a need for novel therapies that can achieve functional or complete cure by targeting key components of the virus. This review discusses current best practices for managing chronic HBV infection and new emerging therapies with the potential for a cure.

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Hepatitis E prevalence and infection in solid-organ transplant recipients in the United States

Niharika Samala, Richard Y. Wang, Sungyoung Auh, Abdalla Kara Balla, Lara Dakhoul, Harvey J. Alter, Patrizia Farci, Marwan Ghabril, Michael R. Lucey, Amol S. Rangnekar, K. Rajender Reddy, Marc G. Ghany

Summary: Hepatitis E virus infection is more prevalent in organ transplant recipients, especially among older individuals and those who have undergone kidney transplantation. The detection of HEV should be considered in transplant patients presenting with graft hepatitis, although chronic HEV infection is rare.

JOURNAL OF VIRAL HEPATITIS (2022)

Article Multidisciplinary Sciences

Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C

Akira Nishio, Sharika Hasan, Heiyoung Park, Nana Park, Jordan H. Salas, Eduardo Salinas, Lela Kardava, Paul Juneau, Nicole Frumento, Guido Massaccesi, Susan Moir, Justin R. Bailey, Arash Grakoui, Marc G. Ghany, Barbara Rehermann

Summary: The humoral response to HCV decreases in potency and breadth after cure of chronic hepatitis C, while HCV-specific memory B cells persist. This finding has implications for the development of an effective vaccine against HCV infection.

NATURE COMMUNICATIONS (2022)

Article Gastroenterology & Hepatology

Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy

Nehna Abdul Majeed, Ahmad Samer Alawad, Kin Seng Liem, Varun Takyar, Harvey Alter, Jordan J. Feld, Harry L. A. Janssen, Marc G. Ghany

Summary: This study evaluated the rate of hepatitis B virus (HBV) reactivation in patients with chronic hepatitis C (CHC) during direct acting antiviral (DAA) therapy. The risk of HBV reactivation was found to be low, and testing for HBV DNA is recommended only in patients with ALT flares or failure of ALT normalization during DAA treatment.

DIGESTIVE DISEASES AND SCIENCES (2023)

Article Gastroenterology & Hepatology

Use of HBV RNA and to predict change in serological status and disease activity in CHB

Marc G. Ghany, Wendy C. King, Amanda S. Hinerman, Anna SF. Lok, Mauricio Lisker-Melman, Raymond T. Chung, Norah Terrault, Harry L. A. Janssen, Mandana Khalili, William M. Lee, Daryl T. Y. Lau, Gavin A. Cloherty, Richard K. Sterling

Summary: This study examined the predictive ability of HBV RNA and HBcrAg for patients with chronic hepatitis B (CHB) and found that they could predict key events such as not sustained inactive carrier phase, ALT flare, HBeAg loss, and HBsAg loss. However, their addition to readily available markers provided only small improvements in predictive ability.

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference

Marc G. Ghany, Maria Buti, Pietro Lampertico, Hannah M. Lee

Summary: Representatives from academia, industry, regulatory agencies, and patient advocacy groups convened under the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) in June 2022 to achieve consensus on chronic HBV and HDV treatment endpoints. The conference focused on the primary goal of guiding clinical trials aiming to cure HBV and HDV, and reached agreements on key points such as preferred endpoints for trials, suitable patient candidates, and the role of novel biomarkers and existing therapies.

HEPATOLOGY (2023)

Meeting Abstract Gastroenterology & Hepatology

NATURAL HISTORY OF INDETERMINANT CHRONIC HEPATITIS B

Donald Wunsch, Elizabeth C. Wright, Sungyoung Auh, Joni Trenbeath, Marc G. Ghany

HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

EFFECT OF HCV ERADICATION WITH SOFOSBUVIR AND VELPATASVIR ON ENDOGENOUS LIPOPROTEIN PATHWAY AND CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS

Zahra Sarrafan-Chaharsoughi, Varun Takyar, Sungyoung Auh, Ahmad Alawad, Brent S. Abel, Devika Kapuria, Colleen Byrnes, Anna Wolska, David E. Kleiner, Robert D. Shamburek, Alan T. Remaley, Marc G. Ghany

HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

HIGH LEVELS OF INTRAHEPATIC INTEGRATED HBV DNA THAT CORRELATED WITH SERUM QUANTITATIVE HBsAg LEVEL IN HBEAG NEGATIVE CHRONIC HEPATITIS B

Daryl Lau, Elena Kim, Chosha Bai, Wendy King, Yixiao Cui, David E. Kleiner, Marc G. Ghany, Thi Thuy Tu Nguyen, Amanda Hinerman, Zhili Wang, Raymond T. Chung, Richard K. Sterling, Gavin A. Cloherty, Ying-Hsiu Su, Haitao Guo

HEPATOLOGY (2022)

暂无数据